Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Inside AstraZeneca’s Long-Term Strategy in Lung Cancer

UNITED STATES, AUG 7 – AstraZeneca aims to treat over 50% of lung cancer patients by 2030 using targeted therapies like Tagrisso and Datroway, improving survival for those with EGFR mutations.

Summary by biopharmadive.com
Decades-long research has yielded a strong and growing franchise built around drugs for a genetic form of lung cancer.

2 Articles

biopharmadive.combiopharmadive.com
Center

Inside AstraZeneca’s long-term strategy in lung cancer

Decades-long research has yielded a strong and growing franchise built around drugs for a genetic form of lung cancer.

Read Full Article
PharmaVOICEPharmaVOICE
Center

Inside AstraZeneca’s long-game strategy in lung cancer

New long-term results for Tagrisso in EGFR-mutated non-small cell lung cancer showcase a precision approach the company has honed for decades.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

PharmaVOICE broke the news in on Thursday, August 7, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal